| Title | Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. | | Author(s) | Yan T, Deng S, Metzger A, Gödtel-Armbrust U, Porter AC, Wojnowski L | | Institution | 1Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany and 2Department of Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom. | | Source | Mol Cancer Ther 2009 May 5. | | Abstract | Coadministration of the iron chelator dexrazoxane reduces by 80% the incidence of heart failure in cancer patients treated with anthracyclines. The clinical application of dexrazoxane is limited, however, because its ability to inhibit topoisomerase IIalpha (TOP2A) is feared to adversely affect anthracycline chemotherapy, which involves TOP2A-mediated generation of DNA double-strand breaks (DSB). Here, we investigated the apoptotic effects of dexrazoxane and the anthracycline doxorubicin, alone and in combination, in a tumor cell line with conditionally regulated expression of TOP2A. Each drug caused apoptosis that was only partly dependent on TOP2A. Unexpectedly, dexrazoxane was found to cause TOP2A depletion, thereby reducing the doxorubicin-induced accumulation of DSB. Despite this latter effect, dexrazoxane showed no adverse effect on doxorubicin-induced apoptosis. This could be explained by the TOP2A-independent apoptotic effects of each drug: those of doxorubicin included TOP2A-independent DSB formation and depletion of intracellular glutathione, whereas those of dexrazoxane were caspase independent. In conclusion, both doxorubicin and dexrazoxane induce apoptosis via TOP2A-dependent and TOP2A-independent mechanisms, the latter compensating for the reduction in cell killing due to dexrazoxane-induced TOP2A depletion. These observations suggest an explanation for the absence of adverse dexrazoxane effects on clinical responses to doxorubicin. [Mol Cancer Ther 2009;8(5):1075-85]. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19417146 |
|
